NasdaqGS - Delayed Quote USD

Recursion Pharmaceuticals, Inc. (RXRX)

Compare
6.67 -0.05 (-0.74%)
At close: October 15 at 4:00 PM EDT
6.74 +0.07 (+1.05%)
Pre-Market: 8:19 AM EDT
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
48,621.00
43,876.00
39,681.00
10,000.00
3,413.00
--
Cost of Revenue
41,123.00
42,587.00
48,275.00
--
--
--
Gross Profit
7,498.00
1,289.00
-8,594.00
10,000.00
3,413.00
--
Operating Expense
402,861.00
351,349.00
237,133.00
192,775.00
88,028.00
--
Operating Income
-395,363.00
-350,060.00
-245,727.00
-182,775.00
-84,615.00
--
Net Non Operating Interest Income Expense
16,346.00
19,019.00
6,199.00
-2,879.00
-1,024.00
--
Other Income Expense
-1,273.00
-1,087.00
52.00
-825.00
-1,367.00
--
Pretax Income
-380,290.00
-332,128.00
-239,476.00
-186,479.00
-87,006.00
--
Tax Provision
-5,364.00
-4,062.00
--
--
--
--
Net Income Common Stockholders
-374,926.00
-328,066.00
-239,476.00
-186,479.00
-87,006.00
--
Diluted NI Available to Com Stockholders
-374,926.00
-328,066.00
-239,476.00
-186,479.00
-87,006.00
--
Basic EPS
-1.66
-1.58
-1.36
-1.49
-0.77
--
Diluted EPS
-1.66
-1.58
-1.36
-1.49
-0.77
--
Basic Average Shares
227,928.74
207,853.70
175,537.49
125,348.11
112,466.06
--
Diluted Average Shares
227,928.74
207,853.70
175,537.49
125,348.11
112,466.06
--
Total Operating Income as Reported
-395,363.00
-350,060.00
-245,727.00
-182,775.00
-84,615.00
--
Total Expenses
443,984.00
393,936.00
285,408.00
192,775.00
88,028.00
--
Net Income from Continuing & Discontinued Operation
-374,926.00
-328,066.00
-239,476.00
-186,479.00
-87,006.00
--
Normalized Income
-374,926.00
-328,066.00
-239,476.00
-185,652.00
-85,639.00
--
Interest Income
16,812.00
19,116.00
6,254.00
73.00
336.00
--
Interest Expense
466.00
97.00
55.00
2,952.00
1,360.00
--
Net Interest Income
16,346.00
19,019.00
6,199.00
-2,879.00
-1,024.00
--
EBIT
-379,824.00
-332,031.00
-239,421.00
-183,527.00
-85,646.00
--
EBITDA
-348,348.00
-307,629.00
-227,665.00
-175,122.00
-81,703.00
--
Reconciled Cost of Revenue
41,123.00
42,587.00
48,275.00
--
--
--
Reconciled Depreciation
31,476.00
24,402.00
11,756.00
8,405.00
3,943.00
--
Net Income from Continuing Operation Net Minority Interest
-374,926.00
-328,066.00
-239,476.00
-186,479.00
-87,006.00
--
Total Unusual Items Excluding Goodwill
--
--
--
-827.00
-1,367.00
--
Total Unusual Items
--
--
--
-827.00
-1,367.00
--
Normalized EBITDA
-348,348.00
-307,629.00
-227,665.00
-174,295.00
-80,336.00
--
Tax Rate for Calcs
0.00
0.00
--
--
--
--
12/31/2019 - 4/16/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers